🧬 4-1BB (CD137) vs CD28 Co-stimulatory Pathways

Vergleich der wichtigsten Kostimulationsdomänen in CAR-T-Zellen

4-1BB (CD137) vs CD28 Co-stimulatory Pathways 4-1BB (CD137) Pathway APC (DC, Macrophage) 4-1BBL T Cell (CD8+/CD4+) 4-1BB CD28 Pathway APC (DC, B cell) B7-1/B7-2 (CD80/CD86) T Cell (Naive/Memory) CD28 4-1BB Effects • Enhanced survival (↑Bcl-XL, ↑Bcl-2) • Sustained proliferation • Memory formation • Late activation (peak day 2-3) • Lower CRS/ICANS risk CD28 Effects • Rapid activation • Strong early expansion • Shorter persistence • Early activation (peak day 1-2) • Higher CRS/ICANS risk 4-1BB Products • Tisagenlecleucel (Kymriah®) • Lisocabtagen-Maraleucel (Breyanzi®) • Idecabtagen-Vicleucel (Abecma®) CD28 Products • Axicabtagen-Ciloleucel (Yescarta®) • Brexucabtagen-Autoleucel (Tecartus®)